Wide complex tachycardia medical therapy: Difference between revisions
Rim Halaby (talk | contribs) |
|||
(8 intermediate revisions by 2 users not shown) | |||
Line 12: | Line 12: | ||
==Overview== | ==Overview== | ||
The management of wide complex tachycardia should begin by assessing the patient's ABCs (airway, breathing, and circulation). If the patient is unstable and either [[hypotension]], [[altered mental status]], [[chest pain]], [[heart failure]] or [[seizures]] are present, then immediate synchronized [[cardioversion]] should be performed. If the patient is stable, the optimal management depends upon the differentiation of [[ventricular tachycardia]] versus [[supraventricular tachycardia]] with aberrant conduction as a cause of the wide complex tachycardia. | The management of wide complex tachycardia should begin by assessing the patient's ABCs (airway, breathing, and circulation). If the patient is unstable and either [[hypotension]], [[altered mental status]], [[chest pain]], [[heart failure]] or [[seizures]] are present, then immediate synchronized [[cardioversion]] should be performed. If the patient is stable, the optimal management depends upon the differentiation of [[ventricular tachycardia]] versus [[supraventricular tachycardia]] with aberrant conduction as a cause of the wide complex tachycardia. '''A wide complex tachycardia should be assumed to be and managed as though it is due to ventricular tachycardia until proven otherwise. This is true even in a hemodynamically stable patient until proven otherwise (VT can often be hemodynamically stable). The initial management strategy includes avoiding the use of a long acting [[AV nodal blocking agent]] and drugs that suppress [[left ventricular contractility]] such as [[verapamil]] which can induce [[hypotension]] in a previously stable patient.''' | ||
==Medical Therapy== | ==Medical Therapy== | ||
Line 30: | Line 30: | ||
{{familytree | | | | E01 | | E02 | | E03 | | E04 | | E05 | | E06 | E01='''[[Ventricular tachycardia]] or uncertain rhythm?'''|E02='''Confirmed [[SVT]] with aberrancy?'''|E03='''[[Afib]] with aberrancy?'''|E04='''Pre-excited [[Afib]] ([[Afib]] + [[WPW]])?'''|E05='''Recurrent polymorphic [[VT]]?'''|E06='''[[Torsade de pointes]]?'''}} | {{familytree | | | | E01 | | E02 | | E03 | | E04 | | E05 | | E06 | E01='''[[Ventricular tachycardia]] or uncertain rhythm?'''|E02='''Confirmed [[SVT]] with aberrancy?'''|E03='''[[Afib]] with aberrancy?'''|E04='''Pre-excited [[Afib]] ([[Afib]] + [[WPW]])?'''|E05='''Recurrent polymorphic [[VT]]?'''|E06='''[[Torsade de pointes]]?'''}} | ||
{{familytree | | | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | }} | {{familytree | | | | |!| | | |!| | | |!| | | |!| | | |!| | | |!| | }} | ||
{{familytree | | | | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | F01=- Give [[amiodarone]] 150 mg IV over 10 min<br><br>- Repeat [[amiodarone]] as needed for a maximal dose of 2.2g/24h<br><br>- Prepare for elective synchronized [[cardioversion]]| F02=- | {{familytree | | | | F01 | | F02 | | F03 | | F04 | | F05 | | F06 | F01=- Give [[amiodarone]] 150 mg IV over 10 min<br><br>- Repeat [[amiodarone]] as needed for a maximal dose of 2.2g/24h<br><br>- Prepare for elective synchronized [[cardioversion]]| F02=- If '''certain''' [[VT]] is '''not''' present, give [[adenosine]] 6 mg rapid IV push<br><br>- If no [[conversion]] give 12 mg IV push<br><br>- May repeat 12 mg dose once| F03=- Consider expert consultation<br><br>- Control rate e.g [[diltiazem]] or [[beta blocker]]s<br>Use [[beta blocker]]s with caution in [[pulmonary disease]]s or [[CHF]]| F04= - Consider expert consultation<br><br>- Avoid AV nodal blocking agents<br>e.g [[adenosine]], [[digoxin]], [[diltiazem]] and [[verapamil]]<br><br>- Consider [[amiodarone]] 150 mg IV over 10 min| F05= Consider expert consultation| F06=Load with [[Magnesium]] 1-2 g over 5-60 min, then infusion}} | ||
{{familytree/end}} | {{familytree/end}} | ||
''Algorithm based on [[ACLS]] guidelines for the management of tachycardia.'' | ''Algorithm based on the 2003 [[ACLS]] guidelines for the management of tachycardia.''<ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598 }} </ref> | ||
==Critical Caveats in the Management of Wide Complex Tachycardia== | |||
* Do not use Ca<sup>2+</sup> channel blocker, [[digoxin]] or [[adenosine]] if you don't not know the etiology of the wide complex tachycardia. Ca<sup>2+</sup> channel blockers and digoxin can lead to accelerated conduction down a bypass tract | *'''[[Verapamil]] should be avoided in patients with wide complex tachycardia as it can result in hemodynamic deterioration in patients with [[ventricular tachycardia]].'''<ref name="pmid3578051">{{cite journal |author=Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME |title=Hazards of intravenous verapamil for sustained ventricular tachycardia |journal=[[The American Journal of Cardiology]] |volume=59 |issue=12 |pages=1107–10 |year=1987 |month=May |pmid=3578051 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0002-9149(87)90857-5 |issn= |accessdate=2013-08-04}}</ref> | ||
* Do not use Ca<sup>2+</sup> channel blocker, [[digoxin]] or [[adenosine]] if you don't not know the etiology of the wide complex tachycardia. Ca<sup>2+</sup> channel blockers and [[digoxin]] can lead to accelerated conduction down a [[bypass tract]] which may in turn degenerate into [[VF]]. | |||
* Though ACLS guidelines recommend a diagnostic trial of [[adenosine]], it can precipitate [[VF]] in some patients with SVT. Patients who have underlying coronary disease may become ischemic from coronary steal. Rhythm can degenerate and lead to [[VF]] that cannot be resuscitated. Furthermore, some [[VT]] (specially those with structurally normal hearts) are [[adenosine]] responsive and can terminate. | * Though ACLS guidelines recommend a diagnostic trial of [[adenosine]], it can precipitate [[VF]] in some patients with SVT. Patients who have underlying coronary disease may become ischemic from coronary steal. Rhythm can degenerate and lead to [[VF]] that cannot be resuscitated. Furthermore, some [[VT]] (specially those with structurally normal hearts) are [[adenosine]] responsive and can terminate. | ||
*:# Etiology uncertain | *:# Etiology uncertain |
Latest revision as of 16:33, 5 August 2013
Resident Survival Guide |
File:Physician Extender Algorithms.gif |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Rim Halaby
Overview
The management of wide complex tachycardia should begin by assessing the patient's ABCs (airway, breathing, and circulation). If the patient is unstable and either hypotension, altered mental status, chest pain, heart failure or seizures are present, then immediate synchronized cardioversion should be performed. If the patient is stable, the optimal management depends upon the differentiation of ventricular tachycardia versus supraventricular tachycardia with aberrant conduction as a cause of the wide complex tachycardia. A wide complex tachycardia should be assumed to be and managed as though it is due to ventricular tachycardia until proven otherwise. This is true even in a hemodynamically stable patient until proven otherwise (VT can often be hemodynamically stable). The initial management strategy includes avoiding the use of a long acting AV nodal blocking agent and drugs that suppress left ventricular contractility such as verapamil which can induce hypotension in a previously stable patient.
Medical Therapy
Wide complex tachycardia QRS ≥ 120ms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do the following simultaneously: - Assess and support ABC's as needed - Give oxygen - Monitor ECG, BP, oxymetry - Identify and treat reversible causes (hypokalemia, hypomagnesemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is the patient stable? Unstable signs include: - Chest pain - Congestive heart failure - Hypotension - Loss of consciousness - Seizures | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Is the rhythm regular? | Immediate synchronized cardioversion -Establish IV access - Give IV sedation if the patient is conscious - Consider expert consultation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regular rhythm | Irregular rhythm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ventricular tachycardia or uncertain rhythm? | Confirmed SVT with aberrancy? | Afib with aberrancy? | Pre-excited Afib (Afib + WPW)? | Recurrent polymorphic VT? | Torsade de pointes? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
- Give amiodarone 150 mg IV over 10 min - Repeat amiodarone as needed for a maximal dose of 2.2g/24h - Prepare for elective synchronized cardioversion | - If certain VT is not present, give adenosine 6 mg rapid IV push - If no conversion give 12 mg IV push - May repeat 12 mg dose once | - Consider expert consultation - Control rate e.g diltiazem or beta blockers Use beta blockers with caution in pulmonary diseases or CHF | - Consider expert consultation - Avoid AV nodal blocking agents e.g adenosine, digoxin, diltiazem and verapamil - Consider amiodarone 150 mg IV over 10 min | Consider expert consultation | Load with Magnesium 1-2 g over 5-60 min, then infusion | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Algorithm based on the 2003 ACLS guidelines for the management of tachycardia.[1]
Critical Caveats in the Management of Wide Complex Tachycardia
- Verapamil should be avoided in patients with wide complex tachycardia as it can result in hemodynamic deterioration in patients with ventricular tachycardia.[2]
- Do not use Ca2+ channel blocker, digoxin or adenosine if you don't not know the etiology of the wide complex tachycardia. Ca2+ channel blockers and digoxin can lead to accelerated conduction down a bypass tract which may in turn degenerate into VF.
- Though ACLS guidelines recommend a diagnostic trial of adenosine, it can precipitate VF in some patients with SVT. Patients who have underlying coronary disease may become ischemic from coronary steal. Rhythm can degenerate and lead to VF that cannot be resuscitated. Furthermore, some VT (specially those with structurally normal hearts) are adenosine responsive and can terminate.
- Etiology uncertain
- Pronestyl 15 mg/kg load over 30 minutes then 2-6 mg/min gtt
- Ventricular tachycardia with active ischemia
- Lidocaine 1 mg/kg q5-10 min up to 3 times then 2-6 mg/min gtt
- If unsuccessful, pronestyl as above
- If unsuccessful, IV amiodarone 150-300 load over 15-20 min. 30-60 mg/hr gtt for total of 1 gram
- Ventricular tachycardia in setting of cardiomyopathy
- Positively SVT with aberrancy
- Antidromic AVRT
- Etiology uncertain
References
- ↑ Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ; et al. (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". J Am Coll Cardiol. 42 (8): 1493–531. PMID 14563598.
- ↑ Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME (1987). "Hazards of intravenous verapamil for sustained ventricular tachycardia". The American Journal of Cardiology. 59 (12): 1107–10. PMID 3578051. Retrieved 2013-08-04. Unknown parameter
|month=
ignored (help)